ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 172 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2015. The put-call ratio across all filers is 1.39 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2017 | $1,274,000 | -78.8% | 18,795 | -78.0% | 0.00% | -80.0% |
| Q4 2016 | $6,017,000 | -1.4% | 85,583 | -0.5% | 0.02% | 0.0% |
| Q3 2016 | $6,102,000 | +50.1% | 86,025 | +3.5% | 0.02% | +50.0% |
| Q2 2016 | $4,064,000 | -1.1% | 83,089 | +28.1% | 0.01% | 0.0% |
| Q1 2016 | $4,108,000 | -50.8% | 64,880 | -12.9% | 0.01% | -47.4% |
| Q4 2015 | $8,358,000 | +33.7% | 74,507 | +14.8% | 0.02% | +35.7% |
| Q3 2015 | $6,249,000 | -5.9% | 64,880 | 0.0% | 0.01% | +7.7% |
| Q2 2015 | $6,643,000 | +65.4% | 64,880 | +0.3% | 0.01% | +62.5% |
| Q1 2015 | $4,016,000 | +41.5% | 64,680 | 0.0% | 0.01% | +33.3% |
| Q4 2014 | $2,838,000 | -22.5% | 64,680 | 0.0% | 0.01% | -25.0% |
| Q3 2014 | $3,661,000 | +25.7% | 64,680 | -0.3% | 0.01% | +33.3% |
| Q2 2014 | $2,912,000 | -8.2% | 64,880 | 0.0% | 0.01% | -14.3% |
| Q1 2014 | $3,172,000 | – | 64,880 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |